LeMaitre Vascular (LMAT) Competitors

LeMaitre Vascular (NASDAQ:LMAT) and Glaukos (NYSE:GKOS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Do insiders and institutionals hold more shares of LMAT or GKOS?

84.6% of LeMaitre Vascular shares are held by institutional investors. Comparatively, 99.0% of Glaukos shares are held by institutional investors. 9.5% of LeMaitre Vascular shares are held by insiders. Comparatively, 5.8% of Glaukos shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Is LMAT or GKOS more profitable?

LeMaitre Vascular has a net margin of 19.96% compared to Glaukos' net margin of -31.40%. LeMaitre Vascular's return on equity of 13.53% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	19.96%	13.53%	9.78%
Glaukos	-31.40%	-10.66%	-8.06%

Do analysts rate LMAT or GKOS?

LeMaitre Vascular currently has a consensus price target of $97.83, suggesting a potential upside of 19.59%. Glaukos has a consensus price target of $134.67, suggesting a potential upside of 42.76%. Given Glaukos' stronger consensus rating and higher possible upside, analysts plainly believe Glaukos is more favorable than LeMaitre Vascular.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Glaukos	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Does the media prefer LMAT or GKOS?

In the previous week, LeMaitre Vascular had 2 more articles in the media than Glaukos. MarketBeat recorded 6 mentions for LeMaitre Vascular and 4 mentions for Glaukos. LeMaitre Vascular's average media sentiment score of 1.17 beat Glaukos' score of 1.05 indicating that LeMaitre Vascular is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LeMaitre Vascular	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Glaukos	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility & risk, LMAT or GKOS?

LeMaitre Vascular has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. Comparatively, Glaukos has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500.

Which has stronger valuation and earnings, LMAT or GKOS?

LeMaitre Vascular has higher earnings, but lower revenue than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than LeMaitre Vascular, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$219.86M	8.41	$44.04M	$1.98	41.32
Glaukos	$383.48M	14.06	-$146.37M	-$2.37	-39.80

Summary

LeMaitre Vascular beats Glaukos on 9 of the 15 factors compared between the two stocks.